Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update Meeting Abstract


Authors: Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; Vos, S. E.; Holte, H.; Linton, K. M.; Aqeel, A.; Wang, L.; Dinh, M.; Elliott, B.; Belada, D.
Abstract Title: Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update
Meeting Title: 2022 Lymphoma, Leukemia and Myeloma Congress
Journal Title: American Journal of Hematology
Volume: 97
Issue: Suppl. 3
Meeting Dates: 2022 Oct 18-22
Meeting Location: New York, NY
ISSN: 0361-8609
Publisher: John Wiley & Sons, Inc.  
Date Published: 2022-10-01
Start Page: S31
Language: English
ACCESSION: WOS:000866743000051
PROVIDER: wos
PUBMED: 36227644
DOI: 10.1002/ajh.26736
Notes: Meeting Abstract: P-049 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lorenzo Falchi
    108 Falchi